Tymlos
(Abaloparatide)ApprovedPeptide
This medication is a synthetic hormone injection used to treat osteoporosis in postmenopausal women and men at high risk of bone fractures. It works by stimulating the body to build new bone tissue and increase bone strength and density.[2] Tymlos is currently approved and in use across 6 indications[4].[1]
Tymlos is one of 136 small molecule programs targeting Spinal Fusion. It is currently in Approved.
6
Indications
12
Total Trials
3
Active Trials
135
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Tymlos
RRadius Health, Inc.
Approved
Xarelto
WWim Janssens
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
EXPAREL
Pacira Pharmaceuticals, IncPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Zanaflex
LLegacy Health System
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Bupivacain
IIstanbul University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoporosis2 trials
Myelodysplastic Syndromes1 trial
Spinal Fusion1 trial
Treatment1 trial
Sequential Therapies After Osteoanabolic Treatment
Recruiting·—··NCT06164795·150 enrolled
6 more indications
Postmenopausal Women1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Apr 28, 2017
TYMLOS
NDA NDA208743
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tymlos drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Abaloparatide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Tymlos. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Modality
- Peptide[3]
- Highest Phase
- Approved[1]
- Company
- RRadius Health, Inc.